An interim report evaluating the feasibility of myeloablative therapy followed by peripheral blood stem cell (PBSC) autotransplant in patients aged Ͼ60 years is presented. In the last 2 years 19 patients Ͼ60 years old with several oncological conditions, mostly hematological, underwent PBSC autotransplant either as salvage therapy following relapse or resistance to conventional treatment, or as consolidating therapy as a part of a well defined protocol. There were 13 males and six females; the mean age was 66.9 years (range 61-76 years); nine patients had resistant or relapsed lymphoma, six myeloma, two acute leukemia, one Waldenstrom's disease and one lung cancer. . Major responses were obtained in 15 of 16 patients evaluable for response and eight patients entered CR; overall eight patients are in CR, five are alive with disease, five are dead from disease progression and one is dead because of congestive heart failure 7 months following PBSC autotransplant. No early deaths following the procedure occurred; major side-effects were grade I-II mucositis (58%), fever with documented sepsis (10%), pneumonia (5%), cardiac, renal and liver toxicity (5%). Cardiac function was evaluated before and after myeloablative therapy by VEF in all patients; no significant modifications were necessary. In conclusion, our experience demonstrates that myeloablative therapies in older selected patients can be feasible; the feasibility of introducing PBSC 
The use of myeloablative therapy with autologous bone marrow or peripheral stem cell support is now accepted world wide as potentially curative in a variety of neoplastic diseases expecially lymphomas, myelomas and acute myeloid leukemia. [1] [2] [3] [4] [5] [6] [7] Nevertheless most reports focus on patients younger than 60 years due to higher procedurerelated risk in older patients. [6] [7] [8] Few reports concerning the use of high-dose therapy and autologous bone marrow 6, 8 or peripheral stem cell transplantation 9, 10 in the elderly are available, although growing interest in treating older patients has been shown. 11, 12 In addition, from an epidemiological point of view, more than 50% of hematological neoplasms are diagnosed in the elderly. 13, 14 For this reason and because of the need to test feasibility of myeloablative therapy, studies are warranted in patients older than 60 years with the specific purpose of increasing the number of patients receiving potentially curative programs including high-dose therapy and PBSC autotransplantation. Here, we present our experience of high-dose therapy in a subset of patients aged Ͼ60 years with different onco-hematological diseases.
Patients and methods
Since January 1997, 19 patients aged Ͼ60 years with malignant diseases have undergone myeloablative therapy followed by peripheral blood stem cell (PBSC) autotransplant. Patients with resistant or relapsed diseases after previous therapies received PBSC autotransplants, and patients included in prospective therapeutic programs with highdose therapy and PBSC autotransplant were also evaluated. Exclusion criteria were liver and renal dysfunction or major cardiac problems documented prior to the start of the program. Informed consent to undertake an experimental procedure was requested from all patients. Table 1 summarizes the principal clinical and diagnostic data of patients. The Table 1 Principal clinical characteristics of patients older than 60 years who underwent PBSC autotransplant following myeloablative therapy for multiple myeloma, FLAG 17 at reduced dose for AML, the GIMEMA protocol for ALL or byphenotypic leukemia 18 and a combination of cisplatinum and vinorelbin for lung carcinoma. Patient status at PBSC autotransplant was relapse for eight patients (seven lymphomas, one myeloma), resistance for eight patients (two lymphomas, four myelomas, one carcinoma and one Waldenstrom's disease), complete remission for three patients (two leukemias and one myeloma). The first patient underwent the procedure in January 1996, and the last in October 1998; mean follow-up is 10.05 months (range 1-20 months).
Mobilization of CD34
+ cells
+ cells was carried out by a combination of high-dose cyclophosphamide (CTX) and G-CSF 5 g/kg/day until collection. CTX was planned at 3 to 5 g/m 2 depending on the status of the patient. In particular, patients older than 70 years always received a lower dose of CTX. Other therapies were selected taking into account amount of previous therapy and cardiological status including high blood pressure or presence of arrhythmias. Four patients received 3 g/m 2 , five patients 4 g/m 2 and 10 patients 5 g/m 2 of CTX, respectively. CTX and G-CSF were given as usual. 19 Collections were planned when CD34
+ cell count reached a minimum of 20/l in peripheral blood and the target objective was a minimum total number of 2.5 × 10 6 /kg.
Myeloablative therapies
Myeloablative therapies used were among schemes already described in the literature or were parts of protocols under investigation in multi-institutional studies. Table 2 shows the details of schemes used. Patients who had received previous mobilizing therapy with CTX at higher doses or who had received a significant amount of potentially cardiotoxic drugs, underwent a protocol excluding CTX. To minimize mucositis, the dose of melphalan and busulfan was reduced by 20% in all protocols. Five patients with lymphoma received the BEAM regimen, 20 10 a combination of busulfan and melphalan (Bu-MPH), 21 three patients a combination of busulfan and CTX (Bu-CTX), and the one with lung cancer a combination of VP-16 and CTX. 
Supportive therapy
Prophylaxis for bacteria was ciprofloxacin given orally, for herpes virus acyclovir and for fungus low dose (10 mg/day) intravenous amphotericin-B and nystatin. These were given to all patients from the beginning of myeloablative therapy until 2 weeks after complete hematological recovery. In the event of fever during cytopenia empiric broad spectrum antibiotic therapy was immediately started with the combination of two antibiotics (cefalosporin plus amikacin) in patients with no central venous device or three antibiotics (cefalosporin, amikacin and vancomicin or teicoplanin) in patients with a central venous catheter. Transfusions of blood components were as follows: hemoglobin levels were maintained above 9.0 g/100 ml with packed red cells and platelets were transfused when less than 10 000/l or less than 20 000/l in the event of fever. These were apheresis platelet concentrates, if available, or otherwise standard concentrates. All transfusion products were filtered for CMV prevention.
Evaluation of general toxicity
Monitoring of toxicity included evaluation of major sideeffects such as mucositis, signs of heart failure and other major organ dysfunction. Renal and liver function, coagulation parameters, electrolytes, urine and glucose analysis were tested daily with weekly electrocardiograms and chest X-rays. Immediately before myeloablative therapy and before discharge an evaluation of ventricular ejection fraction (VEF) was undertaken as described below. Blood cultures were taken at each fever episode occurring during cytopenia. Presence of CMV antigenemia was assessed weekly in patients at risk such as those with myeloma. All patients underwent daily full blood counts with a differential count.
Inclusion criteria for myeloablative therapy were virtually normal renal function with a creatinine not exceeding 2.0 mg/dl, no elevation of ALT, bilirubin up to twice normal, no signs of heart dysfunction assessed by electrocardiography and ecography, with a minimum VEF of 50%.
Toxicity was graded according to the WHO scale, taking into account acute toxicity (while on therapy) and delayed toxicity (after discharge).
Ventricular ejection fraction (VEF)
Before entering the myeloablative program, all the patients had their VEF assessed. Monitoring of VEF was also carried out before and after mobilization of CD34
+ cells and at the end of the PBSC autotransplantation programme. The transthoracic echocardiogram (M-mode; B-mode; color continued pulsated doppler) was with standard projections with an ATL Apogee CX 2.3 and a probe of 3.5 Mhz: long parasternal axis, short parasternal axis, subcostal chamber, apical chambers, either at rest or left decubitus in the orthopnoic position. VEF was calculated in two and four chambers with the method of square-length.
Results

Mobilization, collection and engraftment data
All patients attained the minimum number of CD34 + cells required with, respectively, one apheresis in one patient, two aphereses in 14 patients, three aphereses in three patients and four aphereses in one patient. The minimum number of 20 CD34
+ /l was reached between days 9 and 14 (median 11) in all patients, the only exception being the patient with Waldenstrom's disease (patient 9) who never attained the target number of 20 CD34
+ cells/l and required four aphereses to collect 3.03 × 10 
Response and follow-up (Table 1)
Data concerning response relate to patients with measurable disease at the time of PBSC autotransplant, leukemias in remission being excluded. Nine patients obtained a complete remission (CR), six myelomas, two lymphomas and one Waldenstrom's disease. Seven lymphoma patients had reductions of almost 50% in disease manifestations. One patient with carcinoma was primarily resistant. Status at follow-up (1-20 months) showed that nine patients had disease progression 2 to 10 months from PBSC autotransplant (six lymphomas, two leukemias and one with lung cancer), one patient with lymphoma developed lung cancer 14 months following PBSC autotransplant, one patient with lymphoma died of heart congestive failure 7 months following PBSC autotransplant, eight patients are still in complete remission (CR) 1 to 17 months following PBSC autotransplant. A total of six patients died; four from disease progression, one from a second tumor, one from heart congestive failure.
Toxicity and side-effects (Table 3)
No early deaths due to the procedure were recorded. Mucositis was the most frequent side-effect (63%) occurring with all myeloablative therapies. Severity of mucositis was generally mild (grade I-II in 58% of patients) and rarely severe (5%). Nevertheless, patients required parenteral nutrition (80%) for most of their hospital admission (data not shown in the Table) . Sepsis was recorded in two patients, one Staphylococcus epidermidis and the other Staphylococcus aureus. Both patients had a central venous catheter. One patient developed a series of life-threatening complications and side-effects despite rapid hematologic recovery (PMN = 9 days and PLT = 11 days); first pneumonia (no microorganism identified), then pleuro-pericarditis and reversible renal failure. The same patient developed chronic congestive heart failure 2 months following PBSC autotransplant and died 7 months later. Myeloablative therapy was Bu-MPH. Reversible liver toxicity (grade II) was recorded in a patient with multiple myeloma and late (2 months after hospital discharge) congestive heart failure in a 71-year-old man with Waldenstrom's disease who had atrial fibrillation at the time of transplant. VEF carried out before and 1 month after PBSC autotransplant showed no modification of measurable cardiac status by the therapy, with a range between 50% and 81% before, and 55% and 78% after the procedure.
Discussion
There is growing interest in the choice of therapy for patients with hematologic diseases aged Ͼ60 years as shown by the wide number of reports in the literature. [9] [10] [11] [12] [13] However, few reports focus on the use of high-dose myeloablative therapy, and these address only the use of PBSC autotransplants in lymphomas 6, 9, 10 or myelomas. 7 In the last 9 years the introduction of PBSC technology has contributed to the enormous increase in the number of autotransplants carried out each year. 22 The main limitation to wide use of PBSC autotransplants remains cost which must be cost effective. 23 However, with cost minimization the procedure could be affordable for a larger number of patients. 24 Myeloablative therapy and PBSC autotransplantation in a subset of patients hypothetically at higher risk during the procedure such as older patients, raises two main points: toxicity must be acceptable and benefit must be evident.
In costing this study, we were aware that myeloablative therapy is better tolerated when patients are in earlier disease phases due to reduction in cumulative toxicity from other treatments; we started with patients with advanced and mostly resistant disease, and moved on to patients in earlier disease phases. The first five patients with lymphoma were treated with BEAM. 20 These had a good partial response and with the exception of one, who died 16 months after PBSC autotransplant, the others are alive with disease and no major toxicities occurred. The next step was to show feasibility of various protocols in multiple myeloma, Waldenstrom's disease, lung cancer and lymphoma, with the aim of assessing toxicity and efficacy of busulfan and melphalan or cyclophosphamide-based programs. In general, very good responses were observed in myeloma, lymphoma and Waldenstrom's disease with documented remissions. Major side-effects were recorded in one patient with lymphoma with a series of complications involving lung, heart and kidney. Three patients, two leukemias and one myeloma, underwent the procedure while in remission and none experienced major complications, showing that PBSC autotransplantation could be considered in the strategy of front-line therapy.
In summary, our experience demonstrates that myeloablative therapy with BEAM, Bu-MPH or Bu-CTX followed by PBSC autotransplantation in selected patients older than 60 years, is feasible and does not cause unacceptable complications: we identified two articles 9,10 exclusively focused on patients older than 60 years. These reports describe experiences with patients with relapsed or resistant lymphomas treated with myeloablative therapy as salvage treatment 9 and those where it was used as part of front-line therapy. 10 The myeloablative protocol was BEAM. A major difference between the two reports was that the patients selected for myeloablative therapy as up-front treatment were between ages 60 and 65 years, whereas resistantrefractory patients had an age range of between 61 and 72 years which is similar to our experience. The authors conclude that myeloablative therapy followed by PBSC autotransplant could be an affordable procedure in older patients with an acceptable risk if the patients are carefully selected. Indeed, only one toxic death from sepsis was reported. We selected most patients according to two criteria: the first was good cardiac function evaluated by VEF and a good performance status, the second was disease status and its general responsiveness to high-dose therapy. The exception was the patient with lung cancer who had no specific indications for the PBSC procedure, but because of a good performance status, he was assigned a sequence of three myeloablative therapies and PBSC autotransplantation. The plan was interrupted after the first autotransplant because it was totally ineffective.
The use of autotransplant in resistant lymphomas has largely been historical. However, most authors conclude that only patients still responsive to treatment have a chance of cure and myeloablative therapy has generally to be preceded by conventional chemotherapy to assess disease sensitivity. 25 This concept is now largely accepted, but in our set of patients it was difficult to apply, due to prior therapy and the possibility of increased toxicity. We believe that the use of myeloablative therapy as front-line treatment as shown in the article of Moreau et al 10 could be acceptable and feasible in patients older than 65 years with a good performance status. Experience in multiple myeloma with the use of myeloablative therapy is now mature 7, 26 and most trials are including patients up to 60 years of age but generally not exceeding 65 years. Before suggesting myeloablative treatment for patients Ͼ65 years, positive results with this approach must be attained in younger patients. The recent paper by Attal and co-workers seems to substantiate this. 26 The therapy of acute leukemias using myeloablative therapy followed by PBSC autotransplant has been recently introduced and studies are ongoing. 5, 27 We treated two patients with leukemia and our experience confirms feasibility and the lack of procedure-related problems.
In conclusion, our experience shows that myeloablative therapies are now feasible for most patients who may benefit from this approach. Patient age is not a limiting factor if clinical condition is adequate. Efforts should now be focused on specific indications for myeloablative therapies in order to create generally accepted guide lines for future prospective trials.
